BBA
TVTX icon

Baker Bros. Advisors’s Travere Therapeutics TVTX Stock Holding History

Baker Bros. Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,225,255
Closed -$25.8M – 111
2022
Q4 		$25.8M Sell
1,225,255
-2,074,754
-63% -$44M 0.15% 34
2022
Q3 		$81.3M Hold
3,300,009
– – 0.53% 17
2022
Q2 		$80M Hold
3,300,009
– – 0.45% 17
2022
Q1 		$85M Buy
3,300,009
+630,955
+24% +$16.8M 0.49% 16
2021
Q4 		$82.8M Buy
2,669,054
+629,282
+31% +$17.7M 0.4% 22
2021
Q3 		$49.5M Buy
2,039,772
+1,852,857
+991% +$34M 0.22% 38
2021
Q2 		$2.73M Hold
186,915
– – 0.01% 108
2021
Q1 		$4.67M Buy
+186,915
New +$5.16M 0.02% 98
2014
Q2 		– Sell
-197,178
Closed -$4.19M – 109
2014
Q1 		$4.19M Buy
+197,178
New +$3.03M 0.05% 79

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Baker Bros. Advisors's TVTX Position: Q1 2023 in Review

Baker Bros. Advisors sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 1,225,255 shares — an estimated $25.8M sold.

Baker Bros. Advisors first reported a position in TVTX in Q1 2014 and held it in 9 quarters. The position peaked at $85M in Q1 2022. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

  • Baker Bros. Advisors reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,225,255 Travere Therapeutics shares in Q1 2023, an estimated $25.8M.
  • Baker Bros. Advisors first reported a position in Travere Therapeutics in Q1 2014 and held it in 9 quarters.
  • Baker Bros. Advisors's Travere Therapeutics position peaked at $85M in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.